Mutant blood cells that accumulate silently in bone marrow as people age can sharply raise the risk of coronary heart disease years before any symptoms appear. A 2026 study in Nature now shows that sleep and exercise can slow the expansion of these rogue clones, particularly those carrying the JAK2V617F mutation, and reduce plaque buildup in mouse models of atherosclerosis. The findings offer a concrete, drug-free strategy for a condition that affects a growing share of adults over 50 and has, until recently, lacked any proven preventive intervention.
Why mutant blood-cell growth demands attention right now
The condition at the center of this research is clonal hematopoiesis of indeterminate potential, or CHIP. It occurs when a single blood stem cell acquires a genetic mutation and begins producing an outsized share of the body’s white blood cells. These clones carry driver mutations in genes such as JAK2, TET2, DNMT3A, and TP53. By themselves, the mutations rarely cause blood cancer. Their real danger lies in the cardiovascular system. Research published in The New England Journal of Medicine established that CHIP is associated with substantially higher incident coronary heart disease risk, with mutation-specific effects and dose-dependent relationships tied to clone size. The JAK2 V617F variant carried the highest coronary risk among the mutations studied.
Each mutation drives inflammation through a different molecular route. TET2-deficient blood cells, for example, accelerate atherosclerosis by amplifying macrophage inflammatory signaling, with IL-1beta and the NLRP3 inflammasome playing central roles, according to causal experiments in mice. JAK2V617F clones operate through a separate pathway: they trigger the AIM2 inflammasome via oxidative DNA damage and replication stress, worsening plaque formation in animal models, as documented in a separate Nature study. These distinct mechanisms matter because they suggest that any intervention, whether lifestyle-based or pharmaceutical, may need to be tailored to the specific mutation a person carries.
How sleep and physical activity restrain clone expansion
The 2026 Nature study assessed the effects of sleep and exercise across four driver mutations: Jak2, Tet2, Trp53, and Dnmt3a. In mouse models, both adequate sleep and regular physical activity reduced the expansion of JAK2V617F clonal hematopoiesis and limited atherosclerotic consequences. The responses were mutation-dependent, meaning the degree of benefit varied by which gene was mutated. This is a critical detail: it suggests that the same lifestyle change may help one person with CHIP more than another, depending on their specific genetic profile.
The biological logic connecting sleep to heart disease through blood-cell behavior has been building for years. Prior work from the National Institutes of Health has reported that sleep disruption links to atherosclerosis via immune and hematopoietic pathways, describing how fragmented rest alters blood-cell production and immune signaling in ways that promote plaque growth. The 2026 findings extend that work by showing these pathways can be reversed, at least partially, when sleep and activity patterns improve, and that JAK2-driven clones are especially sensitive to these behavioral shifts.
Separately, a China-based cohort study published in JACC: Asia found that a favorable lifestyle score, which included sleep quality and physical activity among its components, was associated with lower coronary artery disease risk among individuals already carrying CHIP mutations. That observational evidence aligns with the experimental mouse data from the Nature paper, creating two independent lines of support for the same core claim: healthy habits can blunt the cardiovascular threat posed by mutant blood cells. While the cohort analysis cannot prove causation, the convergence of human and animal data strengthens the argument that lifestyle is not just a background factor but a direct modifier of clonal behavior.
Gaps between mouse data and clinical prescriptions
No human interventional trial has yet measured changes in clone size after a prescribed sleep or exercise protocol. The mouse experiments provide strong mechanistic evidence, and the observational cohort data point in the same direction, but the specific dose of exercise or hours of sleep needed to meaningfully shrink a JAK2V617F clone in a living person has not been established. Mutation-specific dose-response curves for exercise intensity or sleep duration remain derived only from animal models and population-level associations, not from randomized human trials.
The hypothesis that targeted combinations of sleep extension and resistance training could produce larger reductions in JAK2V617F clone fraction than aerobic exercise alone, potentially by differentially suppressing AIM2 inflammasome activity, is biologically plausible given the known link between JAK2V617F and the AIM2 pathway. Yet no published trial has tested this specific combination head-to-head. The distinction between AIM2-driven inflammation in JAK2 carriers and NLRP3-driven inflammation in TET2 carriers suggests that a single exercise prescription is unlikely to work equally well for all CHIP variants. Instead, future protocols may need to match exercise modality and intensity to the dominant inflammatory pathway in each mutation.
Pharmaceutical approaches are also in early stages. The National Heart, Lung, and Blood Institute has described a sub-analysis indicating that IL-1beta blockade shows benefits among adults with TET2 CHIP who already have heart disease. That finding reinforces the inflammatory mechanism but applies only to people who have already developed symptomatic cardiovascular disease, not to the much larger group of older adults with asymptomatic CHIP detected incidentally. For now, there is no approved drug whose primary indication is to slow clonal hematopoiesis and prevent first cardiovascular events.
This leaves clinicians in a familiar bind: they can identify a risk signal but lack mutation-specific therapies to offer most patients. The emerging sleep and exercise data at least provide a rational, low-risk starting point. Advising CHIP carriers to prioritize consistent sleep schedules, minimize night-shift work when possible, and build a regular activity routine aligns with general cardiovascular guidelines while also targeting the biology of clonal expansion. Until trials define precise thresholds, many experts argue that “more than the minimum” may be a reasonable stance: aiming beyond the standard seven hours of sleep and 150 minutes of moderate exercise per week, provided patients can do so safely.
What this means for screening and prevention
The new findings also sharpen debates about whether to screen for CHIP in the first place. Sequencing panels used in oncology and cardiology already detect these mutations incidentally, but there is no consensus on population-wide testing. One concern has been the absence of clear, evidence-based interventions. As lifestyle strategies gain mechanistic support, that objection weakens, at least for high-risk groups such as older adults with existing coronary disease or strong family histories.
Still, screening raises ethical and practical questions. Not everyone with CHIP will suffer a heart attack or stroke, and telling patients they harbor mutant blood clones without being able to offer targeted drugs could cause anxiety. On the other hand, knowing a person carries a high-risk mutation like JAK2V617F could justify more aggressive counseling on sleep hygiene, structured exercise programs, and control of traditional risk factors such as blood pressure and cholesterol. Over time, mutation-guided lifestyle prescriptions may sit alongside statins and antihypertensives as core tools of cardiovascular prevention.
For now, the message is cautiously optimistic. Clonal hematopoiesis is not destiny. The same behaviors long recommended for heart health appear capable of acting one step upstream, on the mutant cells that quietly accelerate vascular damage. As researchers move from mouse models to carefully designed human trials, the hope is that personalized combinations of sleep, activity, and eventually targeted drugs will turn CHIP from a looming threat into a manageable, modifiable risk factor.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
